{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:28:28Z","timestamp":1787023708889,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Federal Da Bahia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The coexistence of polyarteritis nodosa (PAN) and antiphospholipid syndrome (APS) is rarely reported and remains poorly characterized. Both conditions may involve vascular injury, but through distinct mechanisms\u2014necrotizing inflammation in PAN and thrombotic vasculopathy in APS. Their overlap may result in a unique and potentially severe clinical phenotype, posing diagnostic and therapeutic challenges. In addition, differentiating inflammatory vasculitic injury from thrombotic vascular occlusion may be particularly difficult in this overlap setting, especially in patients with catastrophic presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review all published cases describing the association between PAN and APS, focusing on clinical features, laboratory findings, pathophysiological insights, management strategies, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed\/MEDLINE, Scopus, and Web of Science from inception through 2026. The search included terms related to \u201cpolyarteritis nodosa\u201d and \u201cantiphospholipid syndrome.\u201d Only studies reporting cases fulfilling accepted diagnostic or classification criteria for PAN and APS were included. Data extraction encompassed demographic characteristics, temporal relationship between diseases, clinical manifestations, antiphospholipid antibody profiles, imaging and histopathological findings, treatments, and outcomes. Due to heterogeneity and limited sample size, a descriptive analysis was performed. Because of the rarity of this overlap syndrome, the available evidence consisted predominantly of case reports and small case series, which were critically analyzed within a systematic review framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A small number of cases were identified, all reported as case reports or small case series. Most patients were middle-aged males, although one pediatric case was described. The temporal relationship varied, with simultaneous diagnosis being most common, while in some cases APS developed after PAN onset. Clinically, patients exhibited features of systemic PAN, including visceral involvement, neuropathy, and hypertension, alongside thrombotic events characteristic of APS, such as arterial occlusions, renal infarctions, stroke, and limb ischemia. Antiphospholipid antibodies\u2014particularly anticardiolipin antibodies and lupus anticoagulant\u2014were frequently detected. A distinctive feature was the coexistence of aneurysmal lesions and thrombosis. Treatment generally included corticosteroids and cyclophosphamide, often combined with anticoagulation. Outcomes were heterogeneous, ranging from clinical improvement to severe complications, including amputations and death. Several reports also raised the possibility of catastrophic antiphospholipid syndrome (CAPS), further complicating the distinction between inflammatory multiorgan vasculitis and thrombotic microangiopathic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The association between PAN and APS represents a rare but clinically significant overlap syndrome characterized by the interplay between inflammatory vasculitis and thrombotic mechanisms. Recognition of this entity is essential, as it has important implications for diagnosis and management. Emerging evidence suggests that endothelial dysfunction, complement activation, NETosis, and thromboinflammatory pathways may contribute to the pathogenesis of this overlap phenotype. Future studies are needed to better define its pathogenesis, optimize therapeutic strategies, and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08214-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:56:47Z","timestamp":1782827807000},"page":"4791-4800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polyarteritis nodosa and antiphospholipid syndrome: a systematic review of a rare and challenging overlap between vasculitis and thrombotic vasculopathy"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-0844","authenticated-orcid":false,"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Paulo Correia","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"4","key":"8214_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/BF02230368","volume":"15","author":"R Schoonjans","year":"1996","unstructured":"Schoonjans R, Van Vlem B, Weyers S, De Keyser F, Praet M, Versieck J, Elewaut A (1996) Polyarteritis nodosa and the antiphospholipid syndrome. Clin Rheumatol 15(4):410\u20133. https:\/\/doi.org\/10.1007\/BF02230368","journal-title":"Clin Rheumatol"},{"issue":"11","key":"8214_CR2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/rheumatology\/36.11.1210","volume":"36","author":"B Dasgupta","year":"1997","unstructured":"Dasgupta B, Almond MK, Tanqueray A (1997) Polyarteritis nodosa and the antiphospholipid syndrome. Br J Rheumatol 36(11):1210\u20132. https:\/\/doi.org\/10.1093\/rheumatology\/36.11.1210","journal-title":"Br J Rheumatol"},{"issue":"1","key":"8214_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1191\/096120398678919642","volume":"7","author":"S Morelli","year":"1998","unstructured":"Morelli S, Perrone C, Paroli M (1998) Recurrent cerebral infarctions in polyarteritis nodosa with circulating antiphospholipid antibodies and mitral valve disease. Lupus 7(1):51\u20132. https:\/\/doi.org\/10.1191\/096120398678919642","journal-title":"Lupus"},{"key":"8214_CR4","doi-asserted-by":"publisher","unstructured":"Han BK, Inaganti K, Fahmi S, Reimold A (2004) Polyarteritis nodosa complicated by catastrophic antiphospholipid syndrome. J Clin Rheumatol 10(4):210\u2013213. https:\/\/doi.org\/10.1097\/01.rhu.0000135627.88021.d1","DOI":"10.1097\/01.rhu.0000135627.88021.d1"},{"issue":"4","key":"8214_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/S0482-50042006000400012","volume":"46","author":"IP Costa","year":"2006","unstructured":"Costa IP, Andrade FAM, Horimoto AMC (2006) Associa\u00e7\u00e3o entre poliarterite nodosa e s\u00edndrome antifosfol\u00edpide: relato de caso e revis\u00e3o de literatura. Rev Bras Reumatol 46(4):298\u2013303","journal-title":"Rev Bras Reumatol"},{"issue":"4","key":"8214_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/SMJ.0b013e318167d963","volume":"101","author":"JL Musuruana","year":"2008","unstructured":"Musuruana JL, Cavallasca JA (2008) Polyarteritis nodosa complicated by antiphospholipid syndrome. South Med J 101(4):419\u201321. https:\/\/doi.org\/10.1097\/SMJ.0b013e318167d963","journal-title":"South Med J"},{"issue":"1","key":"8214_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3899\/jrheum.080601","volume":"36","author":"MN Huang","year":"2009","unstructured":"Huang MN, Wu CH (2009) Polyarteritis nodosa and antiphospholipid syndrome causing bilateral renal infarction. J Rheumatol 36(1):197. https:\/\/doi.org\/10.3899\/jrheum.080601","journal-title":"J Rheumatol"},{"key":"8214_CR8","unstructured":"Valeyrie L, Bachot N, Roujeau JC, Authier J, Gherardi R, Hosseini H (2003) Neurological manifestations of polyarteritis nodosa associated with the antiphospholipid syndrome. Ann Med Interne (Paris) 154(7):479\u2013482"},{"key":"8214_CR9","doi-asserted-by":"publisher","unstructured":"Caldas CA, de Carvalho JF (2013) Antiphospholipid syndrome and polyarteritis nodosa: a diagnostic and therapeutic challenge. Rheumatol Int 33(10):2697\u20132698. https:\/\/doi.org\/10.1007\/s00296-012-2495-0","DOI":"10.1007\/s00296-012-2495-0"},{"issue":"1","key":"8214_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxag003","volume":"10","author":"A Nimbvikar","year":"2026","unstructured":"Nimbvikar A, Tudino R, Fahlen C, Long JD, Rosenberg H, Nobee A, Chen D, Reginato A, Artiles MJ (2026) Navigating clinical overlap: a case of polyarteritis nodosa in the setting of antiphospholipid syndrome. Mod Rheumatol Case Rep 10(1):rxag003. https:\/\/doi.org\/10.1093\/mrcr\/rxag003","journal-title":"Mod Rheumatol Case Rep"},{"issue":"8","key":"8214_CR11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/art.41776","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G et al (2021) 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol 73(8):1384\u20131393. https:\/\/doi.org\/10.1002\/art.41776","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"8214_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08214-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:16:25Z","timestamp":1787022985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8214"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08214-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a review article and does not involve human participants or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Artificial intelligence tools were used to assist in language refinement. The authors take full responsibility for the content of the manuscript.","order":4,"name":"Ethics","label":"Use of artificial intelligence","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}